Your browser version may not work well with NCBI's Web applications. More information here...
1: Ann Hematol. 2004 May;83(5):319-21. Epub 2003 Nov 27.Click here to read Links

Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody.

Mourad YA, Taher A, Chehal A, Shamseddine A.

Department of Internal Medicine, American University of Beirut-Medical Center, Box 113-6044, 1107 2802, Beirut, Lebanon.

We report a patient with B-cell prolymphocytic leukemia (PLL) who was treated successfully with the monoclonal anti-CD20 antibody (rituximab). The patient had recurrent infections due to relative neutropenia, secondary to bone marrow infiltration. After treatment with monoclonal anti-CD20 antibodies (rituximab) 375 mg/m(2) weekly for 4 weeks, complete remission was obtained. It was documented by normalization of peripheral blood counts, disappearance of organomegaly, and by molecular cytogenetics-fluorescent in situ hybridization (FISH) on bone marrow cells. She remains in complete remission 8 months following the discontinuation of treatment. This is the second reported case of successful treatment of B-cell PLL with rituximab.

PMID: 15060751 [PubMed - indexed for MEDLINE]

Patient Drug Information